The successful use of the first-generation EGFR kinase inhibitors gefitinib and erlotinib to treat EGFR mutant positive NSCLC in the early 2000s were among the first of these developments to pave the way for targeted therapies in lung cancer [10,11]. The gene discussed is EGFR; the disease is lung cancer.